Updated as of Januaty 11, 2021

1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis ex-U.S. 2. Adults with intermediate or high-risk myelofibrosis 3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute GVHD 5. Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) 6. Co-commercialization in the U.S. with MorphoSys 7. Development in collaboration with MorphoSys 8. In combination with lenalidomide in adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) 9. European rights to Iclusig licensed from ARIAD 10. Adults with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 11. Adults with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 12. Certain development programs conducted in collaboration with Novartis 13. In collaboration with MacroGenics 14. In collaboration with Merus 15. Licensed from Calithera 16. Discovery collaboration with Agenus 17. Worldwide rights to baricitinib licensed to Lilly 18. Approved in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 19. Approved in Europe for adults with moderate to severe atopic dermatitis who are candidates for systemic therapy 20. Worldwide rights to capmatinib licensed to Novartis 21. Approved in the U.S. and Japan for certain patients with NSCLC with MET exon 14 skipping (METex14) mutation 22. Authorized in the U.S. for use under an Emergency Use Authorization (EUA), in combination with remdesivir, for treatment of certain hospitalized patients with suspected or laboratory confirmed COVID-19

The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.